Research programme: stem cell therapeutics - Cellular Dynamics International/National Eye Institute

Drug Profile

Research programme: stem cell therapeutics - Cellular Dynamics International/National Eye Institute

Alternative Names: Retinal disease therapeutics - Cellular Dynamics International/National Eye Institute

Latest Information Update: 27 Sep 2016

Price : $50

At a glance

  • Originator National Eye Institute
  • Developer Cellular Dynamics International; National Eye Institute
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 22 Jun 2016 Cellular Dynamics International establishes CRADA with the National Eye Institute for the development of Stem cell therapeutics in Ocular disorders
  • 10 Nov 2014 Preclinical trials in Age-related macular degeneration in USA (Intraocular)
  • 27 Oct 2014 National Eye Institute awards a $US1.2 million contract to Cellular Dynamics International to manufacture induced pluripotent stem cells
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top